FindTrial
Sign In

Bupropion for the Treatment of Methamphetamine Dependence - 1

Bupropion for the Treatment of Methamphetamine Dependence

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00069251
Enrollment
150
Registered
2003-09-24
Start date
2003-07-31
Completion date
2005-06-30
Last updated
2017-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amphetamine-Related Disorders

Keywords

amphetamine dependence

Brief summary

The purpose of this study is to assess the efficacy and safety of bupropion in reducing methamphetamine use in subjects with methamphetamine dependence

Detailed description

A double-blind, placebo-controlled, parallel-group design study in which 100 subjects will be randomly assigned to placebo or bupropion for 12 weeks with follow-up assessments 4 weeks following treatment. Adaptive randomization will be used to balance treatment groups based on gender.

Interventions

DRUGBupropion

Sponsors

National Institute on Drug Abuse (NIDA)
Lead SponsorNIH

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Subject must have methamphetamine dependence as determined by the DSM-IV diagnosis * Subject must be willing to comply with study procedures. * Ability to verbalize understanding of consent form, provide written consent, and verbalize willingness to complete study procedures * Be able to comply with protocol requirements

Exclusion criteria

* Please contact site for more information.

Design outcomes

Primary

MeasureTime frame
Severity addiction—
Methamphetamine use—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026